Implant Or Insert Patents (Class 424/422)
-
Patent number: 11972369Abstract: A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient's treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.Type: GrantFiled: April 24, 2023Date of Patent: April 30, 2024Assignee: The SottoPelle Group, LLCInventor: Gino Tutera
-
Patent number: 11944780Abstract: Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.Type: GrantFiled: October 24, 2019Date of Patent: April 2, 2024Assignee: InCube Labs, LLCInventor: Mir Imran
-
Patent number: 11931461Abstract: The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 ?m. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.Type: GrantFiled: September 5, 2018Date of Patent: March 19, 2024Assignee: INVENTAGE LAB INC.Inventor: Ju Hee Kim
-
Patent number: 11931454Abstract: The invention is generally related to a soft hydrogel ocular insert that is composed of at least one hydrogel material in fully hydrated state and can be comfortable for wearing. The hydrogel material comprises polymer chains, which are derived from at least one arylborono-containing hydrophilic copolymer and at least one mucoadhesive polymer, and cyclic boronic ester crosslinks for crosslinking those mucoadhesive polymer chains and arylborono-containing hydrophilic copolymer chains to form a 3-dimensional polymer network. Those cyclic boronic ester crosslinks can be hydrolyzed slowly in the tear of the eyes of a patient, resulting in the disintegration (dissolution) of the 3-dimensional polymer network and thereby providing mucoadhesisve polymers and optionally drugs impregnated in the hydrogel ocular insert in a controlled manner.Type: GrantFiled: September 17, 2020Date of Patent: March 19, 2024Assignee: Alcon Inc.Inventors: Junhao Ge, Steve Yun Zhang, Daqing Wu, Jing Cheng
-
Patent number: 11918701Abstract: Disclosed herein is a bio-resistant article comprising a porous metal substrate; a self-assembled monolayer disposed on the substrate; wherein the self-assembled monolayer comprises a coupling agent that has a first end that is reactively bonded to the porous metal substrate and a second end that is reactively bonded to a zwitterionic polymer. Disclosed herein too is a method comprising disposing upon a porous metal substrate a self-assembled monolayer; and bonding the zwitterionic polymer to the self-assembled monolayer.Type: GrantFiled: September 19, 2022Date of Patent: March 5, 2024Assignee: MOTT CORPORATIONInventor: Alex Hill
-
Patent number: 11911572Abstract: A balloon retention urinary catheter includes a porous and spongy distal tip. In one method, a polymer is mixed with sacrificial particles and the mixture is molded in the form of the tip, and then cured. The cured tip is then placed in a solvent in which the sacrificial particles elute from the tip but in which the polymer is insoluble. Once the particles elute out of the polymer in the tip, a softer porous polymeric structure results. The tip may be structured to be softer prior to use or for transformation to a softer state once in the bladder.Type: GrantFiled: May 5, 2022Date of Patent: February 27, 2024Assignee: InnoCare Urologics, LLCInventors: Leonard Pinchuk, Bryan Pinchuk, Gary A. Kalser
-
Patent number: 11826488Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.Type: GrantFiled: October 19, 2018Date of Patent: November 28, 2023Assignee: LifeCell CorporationInventors: Hui Xu, Hui Li, Ming F. Pomerleau, Darin Messina
-
Patent number: 11814427Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: March 24, 2020Date of Patent: November 14, 2023Assignee: RANI THERAPEUTICS, LLCInventor: Mir Imran
-
Patent number: 11806928Abstract: A method for fabricating an article of manufacture includes forming a plurality of layers of the article based on a digital model of the article. Each layer of the plurality of layers may be formed by depositing at least two materials that differ from one another. The at least two materials may be deposited separately or simultaneously. The at least two materials may define separate regions of the layer and, thus, define distinct features of the article, and/or the at least two materials may be mixed or one of the materials may be dispersed throughout the other to define a blended zone in the layer. Blended zones of adjacent layers may be superimposed to define three-dimensional blended zones. A blended zone may be graded to provide transition between separate regions of the article that are formed from two or more different materials. Articles fabricated by such processes are also disclosed.Type: GrantFiled: January 26, 2018Date of Patent: November 7, 2023Assignee: 3D Promed, LLCInventors: Dean E. Cropper, Joseph T. Zachariasen
-
Patent number: 11786612Abstract: Implantable materials may be used as spacers for separating tissues to reduce a dose of radioactivity received by one of the tissues. Applications include introducing a hydrogel spacer to a position between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, Further, there may be a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location and/or a step of visualizing margins of the hydrogel spacer. A hydrogel spacer may comprise a polysaccharide and a radioopaque agent and may be used for fiducial marking.Type: GrantFiled: August 21, 2020Date of Patent: October 17, 2023Assignee: Incept, LLCInventors: Patrick Campbell, Amarpreet S. Sawhney
-
Patent number: 11771800Abstract: The invention relates to a method for manufacturing a calcified tissue substitute, the method comprising: reacting ground nacre, monocalcium phosphate, and water to produce brushite; grinding the brushite; reacting ground nacre with the ground brushite in disodium hydrogenphosphate solution. The invention also relates to a calcified tissue substitute manufactured by the method, use of the calcified tissue substitute for repairing a calcified tissue, and a delivery device for delivering the calcified tissue.Type: GrantFiled: June 1, 2018Date of Patent: October 3, 2023Assignee: Marine Biomedical Pty LtdInventors: Rui Ruan, Ming-Hao Zheng
-
Patent number: 11746333Abstract: Provided herein are synthetic living tissue structures comprising multiple layers of fibers deposited in solidified form from a 3D bioprinter, together with kits and methods of use related thereto. The fibers comprise a plurality of mammalian cells dispensed within a solidified biocompatible matrix. The structural integrity of the fiber is maintained upon and after deposition without any additional crosslinking. The fiber is continuously bioprinted through at least two layers of the structure. In one aspect, synthetic muscle tissue structures exhibit a readily assayable contractile functionality.Type: GrantFiled: June 16, 2016Date of Patent: September 5, 2023Inventors: Simon Beyer, Tamer Mohamed, Sheng Pan, Sam Wadsworth
-
Patent number: 11730858Abstract: Gold implant having a cross-section in the range of 20-100, preferably in the range of 20-40 ?m for use in therapy to prevent or reduce capsular contracture. Further, the invention relates to a method of producing a gold-coated implant.Type: GrantFiled: April 13, 2018Date of Patent: August 22, 2023Assignee: Safe Implant Technology ApSInventor: Gorm Danscher
-
Patent number: 11723956Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.Type: GrantFiled: August 31, 2017Date of Patent: August 15, 2023Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Assistance Publique—Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles—St. Quentin en YvelinesInventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
-
Patent number: 11701450Abstract: The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein can be injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection). In some embodiments, the composition described herein comprises a compressed silk fibroin matrix, which can expand upon injection into the tissue and retain its original expanded volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.Type: GrantFiled: September 22, 2016Date of Patent: July 18, 2023Assignee: TRUSTEES OF TUFTS COLLEGEInventors: Gary G. Leisk, Tim Jia-Ching Lo, Lei Li, Evangelia Bellas, David L. Kaplan
-
Patent number: 11672831Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.Type: GrantFiled: March 20, 2017Date of Patent: June 13, 2023Assignees: Takeda Pharmaceutical Company Limited, Universidad Autónoma de MadridInventors: María Gema Fernández Miguel, Manuel Ángel González De La Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
-
Patent number: 11666552Abstract: The present invention relates to a method for modifying release of a therapeutically active agent from an elastomeric matrix, comprising providing a core comprising an elastomeric matrix and a therapeutically active agent; dipping the core to a coating solution of an elastomer, wherein the elastomer comprises 20-35 wt-% of a filler, calculated from the total amount of filler and elastomer; curing the dipped core to provide a coated core. In this method the dipping is provided as a continuous process by pulling the core through the coating solution, using a pulling speed suitable for providing a coating thickness of ?-IOO the filler is selected from silica, titanium dioxide, barium sulphate, carbon and mixtures thereof; the elastomer comprised in the core and the elastomer comprised in the coating solution are independently selected from poly(dimethyl) siloxanes, polyethylene vinyl acetates (EVAs), polyurethanes (PUs), polyhydroxyethyl methacrylates (PHEMAs) and polymethyl methacrylates (PMMAs).Type: GrantFiled: September 19, 2018Date of Patent: June 6, 2023Assignee: Bayer OYInventors: Manja Ahola, Risto Hakala, Piia Hara, Antti Keinänen, Henriikka Korolainen, Jyrki Pihlaja
-
Patent number: 11661471Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.Type: GrantFiled: January 11, 2022Date of Patent: May 30, 2023Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOCANT-CENTER OF INNOVATION AND BIOTECHNOLOGYInventors: Robert S. Langer, Jeffrey M. Karp, Maria Jose Maio Nunes-Pereira, Ben Ouyang, Lino da Silva Ferreira, Debanjan Sarkar
-
Patent number: 11654250Abstract: Implants are placed in turbinate mucosal tissue using a surgical device having a proximal grip portion and a distal hollow sharp needle portion that is manipulated using the grip portion and inserted submucosally into mucosal turbinate tissue. One or more biodegradable, drug-eluting solid implants are disposed within the needle. The implants have one or more implant withdrawal-discouraging, mucosal tissue-engaging surface features along their length. An actuator disposed within the device is used to deliver one or more of the implants from the needle into the mucosal turbinate tissue and submucosally bury at least one such tissue-engaging feature therein.Type: GrantFiled: March 2, 2020Date of Patent: May 23, 2023Assignee: Medtronic Xomed, Inc.Inventors: Jennifer G. Medina, Drew P. Amery, Dana A. Oliver, Jie Wen
-
Patent number: 11612676Abstract: 3D native tissue-derived scaffolding materials are made in various formats, including but not limited to hydrogel, sponge, fibers, microspheres, and films, all of which function to better preserve natural extracellular matrix molecules and to recapitulate the natural tissue environment, thereby effectively guiding tissue regeneration. Tissue-derived scaffolds are prepared by incorporating a homogenized tissue-derived suspension into a polymeric solution of synthetic, natural, or hybrid polymers. Such tissue-derived scaffolds and scaffolding materials have a variety of utilities, including: the creation of 3D tissue models such as skin, bone, liver, pancreas, lung, and so on; facilitation of studies on cell-matrix interactions; and the fabrication of implantable scaffolding materials for guided tissue formation in vivo.Type: GrantFiled: January 31, 2018Date of Patent: March 28, 2023Assignee: The Trustees of The Stevens Institute of TechnologyInventors: Hongjun Wang, Meng Xu, Deep Parikh, Jin Zou, Weiwei Wang
-
Patent number: 11613115Abstract: A microfilter comprising a polymer layer formed from epoxy-based photo-definable dry film, and a plurality of apertures each extending through the polymer layer. A method of forming a microfilter is also disclosed. The method includes providing a first layer of epoxy-based photo-definable dry film disposed on a substrate, exposing the first layer to energy through a mask to form a pattern, defined by the mask, in the first layer of dry film, forming, from the exposed first layer of dry film, a polymer layer having a plurality of apertures extending therethrough, the plurality of apertures having a distribution defined by the pattern, and removing the polymer layer from the substrate.Type: GrantFiled: April 1, 2011Date of Patent: March 28, 2023Assignee: CREATV MICROTECH, INC.Inventors: Olga V. Makarova, Cha-Mei Tang, Platte T Amstutz
-
Patent number: 11613731Abstract: An organ implant, such as a heart implant, including a support structure having a plurality of pores and defining passages configured for the growth of blood vessels; and stem cells from at least one soft tissue source of a patient deposited into the pores of the support structure is described. The implant is configured to repair a portion of an organ of the patient.Type: GrantFiled: August 22, 2019Date of Patent: March 28, 2023Assignee: P TECH, LLCInventor: Peter M. Bonutti
-
Patent number: 11602539Abstract: The present invention relates to a hemostatic composition and a method for preparing thereof, and more specifically, relates to a hemostatic composition comprising a cross-linked hyaluronic acid derivative matrix which is suitable to be used for hemostasis and a method of preparation of such a composition.Type: GrantFiled: September 6, 2017Date of Patent: March 14, 2023Assignee: BMI KOREA CO., LTDInventors: Min-Kyoung Kim, Koo Woo, Yeong Jun Baik, Kyeong Woo Min
-
Patent number: 11602579Abstract: The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1?). The present invention also relates to methods for producing the biomaterial and uses thereof.Type: GrantFiled: September 20, 2018Date of Patent: March 14, 2023Assignee: NOVADIP BIOSCIENCESInventor: Denis Dufrane
-
Patent number: 11590151Abstract: A pharmaceutical paste formulation containing an active ingredient, an API solubilizer, a cross-linking agent, a consistency improver, a rheology modifier, a humectant, and a liquid base.Type: GrantFiled: August 25, 2020Date of Patent: February 28, 2023Assignee: USPHARMA LTDInventors: Manesh A Dixit, Partha S Sen, Rahul Botkar, Ashim K Sarkar
-
Patent number: 11583613Abstract: Described herein are biomaterials, systems, and methods for guiding regeneration of an epiphyseal growth plate or similar interfacial tissue structures. In one aspect, the disclosed technology can include a biologic material that can comprise one or more of a hydrogel carrier for growth factors and MSCs, chondrogenic and immunomodulatory cytokines, microparticles for prolonged and spatially controlled growth factor delivery; and/or porous scaffold providing mechanical support. The implanted material can be applied via various different modalities depending on the nature of the physeal injury. One modality is an injectable hydrogel and another modality is an implantable hydrogel infused scaffold.Type: GrantFiled: March 3, 2017Date of Patent: February 21, 2023Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Juan M. Taboas, Jingming Chen
-
Patent number: 11529308Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.Type: GrantFiled: August 17, 2020Date of Patent: December 20, 2022Assignee: The Population Council, Inc.Inventor: Bruce Variano
-
Patent number: 11524094Abstract: The present invention relates to porous composite materials and objects such as 3D scaffolds, in particular to bioactive and bioresorbable scaffolds that can be transformed at body temperature.Type: GrantFiled: September 19, 2017Date of Patent: December 13, 2022Assignee: Biomendex OyInventors: Kaarlo Paakinaho, Minna Kellomäki
-
Patent number: 11524032Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: GrantFiled: January 7, 2019Date of Patent: December 13, 2022Assignee: University of Utah Research FoundationInventors: Randon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
-
Patent number: 11505619Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.Type: GrantFiled: December 14, 2018Date of Patent: November 22, 2022Assignee: CSL LimitedInventors: Malgorzata Wygrecka, Marc Nolte, Con Panousis
-
Patent number: 11458075Abstract: Provided is an oral care composition and methods of making and using the same. The composition may include an orally acceptable vehicle, including pectin in an amount of from about 0.1% to about 1% by weight, an anticaries agent; and a moisturizing agent.Type: GrantFiled: October 17, 2016Date of Patent: October 4, 2022Assignee: Colgate-Palmolive CompanyInventors: Stacey Lavender, Najma Khan
-
Patent number: 11432943Abstract: An interbody implant system for use in the spine includes a base comprising two or more bone contacting surfaces, at least one recess in at least one of the two or more bone contacting surfaces, the recess configured for containing a tooth, a deployable tooth to provide fixation between the base and the anatomy of a subject, a break-away bridge between the tooth and the base for providing a first relative position between the tooth and the base, and a locking mechanism for providing a second relative position between the tooth and the base.Type: GrantFiled: March 13, 2019Date of Patent: September 6, 2022Assignee: Carlsmed, Inc.Inventors: Niall Patrick Casey, Michael J. Cordonnier
-
Patent number: 11426489Abstract: Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit osteogenic, osteoinductive, osteoconductive, and/or osteostimulative properties.Type: GrantFiled: July 28, 2015Date of Patent: August 30, 2022Assignee: Globus Medical, Inc.Inventors: Jennifer Klimek, Archana Bhat, Vipin Kunjachan, Chris Geisler, Allison Adams, Christine Grimes
-
Patent number: 11406739Abstract: Provided is a method for construction of bone substitutes efficient in the repair of large bone defects. The method for constructing such medical products includes three-dimensional printing of a bioresorbable scaffold and its activation by gene constructions. Produced medicinal products may serve as an efficient alternative to bone autografts.Type: GrantFiled: April 6, 2017Date of Patent: August 9, 2022Assignee: “NEXTGEN” COMPANY LIMITEDInventors: Roman Vadimovich Deev, Artur Aleksandrovich Isaev, Ilya Yadigerovich Bozo, Vladimir Sergeevich Komlev, Alexey Yurevich Drobyshev
-
Patent number: 11406684Abstract: The purpose of the present invention is to provide a novel medicinal agent that is therapeutically more effective than conventional medicinal agents. The purpose is achieved by providing a fine nano-sized medicinal agent in which an active ingredient dispersed in a solvent has an average particle diameter of 1-20 nm.Type: GrantFiled: August 25, 2017Date of Patent: August 9, 2022Inventor: Tetsuji Okuno
-
Patent number: 11389562Abstract: According to some aspects of the invention a method for creation of a wound covering with haemostatic action includes: applying to an open wound a cell structure (grid)-forming water-soluble haemostatic composition designated as a Hemoblok consisting of a polyacrylic matrix as an active ingredient, where the matrix includes one or more polymeric carboxylic acid of a predetermined average molecular weight range, and a bactericidal agent; creating by Hemoblok on a wound surface a structure clot formation with blood plasma proteins, including albumin; creating by Hemoblok on the wound, a covering containing albumin molecules in cells of a polyacrylic structure matrix (grid), which is a primary organizer of sustainable grid structure clot film; further supplying of Hemoblok on an open wound surface to form a multilayered solid grid structure film; terminating of Hemoblok supply on a wound surface with following gradual replacement of a surface structure hemoblok-protein by fibrin.Type: GrantFiled: August 14, 2017Date of Patent: July 19, 2022Inventors: Alexander Plotkin, Dmitri Menglet
-
Patent number: 11393569Abstract: A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient's treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.Type: GrantFiled: February 24, 2020Date of Patent: July 19, 2022Assignee: The SottoPelle Group, LLCInventor: Gino Tutera
-
Patent number: 11376346Abstract: Described herein are compositions comprising decellularized extracellular matrix derived from skeletal muscle or other suitable tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damage, ischemic, ulcer cells, tissues or organs in a subject preferably a human, with diseases associated with muscular degeneration, using a decellularized extracellular matrix of the invention are provided. Methods of preparing culture surfaces and culturing cells with absorbed decellularized extracellular matrix are provided.Type: GrantFiled: May 16, 2018Date of Patent: July 5, 2022Assignee: The Regents of the University of CaliforniaInventors: Karen Christman, Marianna Alperin, Pamela Duran
-
Patent number: 11357756Abstract: Effective implantable medical devices and methods for reducing and treating acute pain by providing local anesthesia and nerve blockade using an imidazoline compound, such as clonidine are provided. In some embodiments, there is an injectable pharmaceutical composition comprising a therapeutically effective amount of imidazoline compound in a liquid pharmaceutical carrier, where the imidazoline compound provides local anesthesia and nerve block to the target tissue site which is a dorsal root ganglion, peripheral nerve fiber and/or peripheral nerve root.Type: GrantFiled: January 19, 2018Date of Patent: June 14, 2022Assignee: Warsaw Orthopedic, Inc.Inventor: Jared T. Wilsey
-
Patent number: 11345881Abstract: The present disclosure relates to a nanofiber structure for cell culture, a method for manufacturing the structure, and a cell analysis device including the nanofiber structure for cell culture. The structure includes a cell culture layer made of nanofibers; and a spacer protruding upward from a surface of the cell culture layer, wherein the spacer divides a region on the cell culture layer into at least two culturing regions, wherein the spacer is made of the same nanofibers as the cell culture layer and thus has a cell migration channel defined therein.Type: GrantFiled: December 8, 2016Date of Patent: May 31, 2022Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION OF AJOU UNIVERSITYInventors: Jong-Young Kwak, Young-Hun Jeong, Jeong-Hwa Kim, Tae-Eon Kim
-
Patent number: 11311643Abstract: Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlled hydrolysis, desirably base-catalyzed, to prepare a fibrin hydrolysate material with increased water sorption capacity. Such fibrin hydrolysate materials, alone or combined with one or more additional substances, can be used in the preparation of hemostasis promoting foams, powders or gels. In some embodiments, a starting dialdehyde starch material is subjected to controlled hydrolysis to prepare a dialdehyde starch hydrolysate material. Such dialdehyde starch hydrolysate materials, alone or combined with one or more additional substances, in some cases combined with a fibrin hydrolysate material, can be used in the preparation of hemostasis promoting foams, powders or gels.Type: GrantFiled: October 10, 2018Date of Patent: April 26, 2022Assignee: Cook Biotech IncorporatedInventors: Niraj Ramachandran, Brooke Lynn Davisson
-
Patent number: 11291630Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.Type: GrantFiled: September 16, 2016Date of Patent: April 5, 2022Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
-
Patent number: 11278493Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.Type: GrantFiled: December 9, 2019Date of Patent: March 22, 2022Assignee: ETERNATEAR, INC.Inventors: Timothy R. Willis, Ralph P. Stone
-
Patent number: 11267851Abstract: An antimicrobial adhesive protein, an antimicrobial nanoparticle, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described and, more particularly, an antimicrobial adhesive protein in which an antibiotic peptide is linked to a mussel adhesive protein, a mussel adhesive protein derivative of which a tyrosine residue within the antimicrobial adhesive protein is modified with a catechol derivative, an antimicrobial nanoparticle including a metal capable of forming a coordinate bond with a derivative of the mussel adhesive protein and having intrinsic antimicrobial activity, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described.Type: GrantFiled: July 13, 2018Date of Patent: March 8, 2022Assignees: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Hyung Joon Cha, Yun Kee Jo, Yeonsu Jeong
-
Patent number: 11237991Abstract: A processing accelerator includes a shared memory, and a stream accelerator, a memory-to-memory accelerator, and a common DMA controller coupled to the shared memory. The stream accelerator is configured to process a real-time data stream, and to store stream accelerator output data generated by processing the real-time data stream in the shared memory. The memory-to-memory accelerator is configured to retrieve input data from the shared memory, to process the input data, and to store, in the shared memory, memory-to-memory accelerator output data generated by processing the input data. The common DMA controller is configured to retrieve stream accelerator output data from the shared memory and transfer the stream accelerator output data to memory external to the processing accelerator; and to retrieve the memory-to-memory accelerator output data from the shared memory and transfer the memory-to-memory accelerator output data to memory external to the processing accelerator.Type: GrantFiled: August 17, 2020Date of Patent: February 1, 2022Assignee: TEXAS INSTRUMENTS INCORPORATEDInventors: Mihir Mody, Niraj Nandan, Hetul Sanghvi, Brian Chae, Rajasekhar Reddy Allu, Jason A. T. Jones, Anthony Lell, Anish Reghunath
-
Patent number: 11229607Abstract: The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject.Type: GrantFiled: June 30, 2015Date of Patent: January 25, 2022Assignee: President and Fellows of Harvard CollegeInventors: Jae-Won Shin, Angelo S. Mao, Stefanie Utech, David A. Weitz, David J. Mooney, Oktay Uzun
-
Patent number: 11229724Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.Type: GrantFiled: June 4, 2020Date of Patent: January 25, 2022Assignee: Tricol Biomedical, Inc.Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
-
Patent number: 11219706Abstract: Provided are formulations and related methods, for coating or impregnating a medical device, as well as a coated or impregnated medical device, for example, a device that is a catheter or cannula, where a different formulation may be used for interior surface of device and for exterior surface of the device.Type: GrantFiled: February 10, 2020Date of Patent: January 11, 2022Assignee: ARROW INTERNATIONAL LLCInventors: Kamma Giare-Patel, Nisha Gupta, Greg Etter, Kevin Sechrist, Molly Stewart, Igor Tentler, Al Williams
-
Patent number: 11191868Abstract: The present patent application is directed to compositions and shaped structures implantable into mammalian bodies, the compositions and shaped structures having localized bioactive surfaces.Type: GrantFiled: July 10, 2019Date of Patent: December 7, 2021Assignee: SYNERGY BIOMEDICAL, LLCInventor: Mark D. Borden
-
Patent number: RE49741Abstract: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.Type: GrantFiled: June 12, 2020Date of Patent: December 5, 2023Assignee: Vivesto ABInventors: Julian Aleksov, Igor Lokot